ArticleFrontiers in immunology2025
The impact of intravenous immunoglobulin therapy on resource utilization associated with viral respiratory tract infections.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immunocompromised patients with moderate to severe viral respiratory tract infections (VRTIs) may benefit from intravenous immune globulin (IVIG) in combination with antivirals. The impact of this therapy on hospital resource utilization is unknown. The purpose of this study was to assess clinical outcomes and hospital resource utilization associated with IVIG use in immunocompromised patients hospitalized with VRTIs. Methods: Using the Premier Healthcare Database, data from 1,927 inpatients with immune deficiency and acute VRTI were analyzed. Outcomes included measures relevant to hospital resource use and patient death rates. Descriptive statistics were used to measure factors associated with IVIG use across the hospital stay. A logistic regression model adjusted for factors associated with the probability of IVIG use within 48 hours of admission. The propensity score was used to weigh subsequent models to assess the length of stay (total and ICU) using a negative binomial model and logistical regression for inpatient death. Results: Of the 1,927 patients analyzed, 65 received IVIG. When adjusting for IVIG use within 48 hours of admission and other patient and hospital characteristics, findings showed a significantly shorter hospital length of stay for patients with acute VRTIs when IVIG was given (p = 0.027). The length of ICU stay was also significantly shorter with IVIG use (p = 0.003). Discussion: Immunocompromised patients with VRTIs who receive IVIG within 48 hours of ICU admission may have a shorter ICU length of stay and shorter overall hospital length of stay thereby possibly decreasing healthcare resource use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.